...Vancouver-based Cardiome Pharma slipped four cents to $4.53, ending the week higher by one per cent. On Thursday, competitor Sanofi-Aventis received U.S. FDA approval for Multaq, a new drug therapy for irregular heartbeat. Last August, Cardiome's shares fell...

...a higher unemployment rate of 9.6 per cent. The jobless rate in May was 9.4 per cent. In Paris corporate news, drug maker Sanofi Aventis added 1.15 per cent to close at 42.81 euros on its plans to double sales in emerging market countries by 2013 and news...

...as the third-largest drug with sales of $7 billion plus. Interestingly, the fast-growing insulin brand Lantus, from Sanofi-Aventis, could be the fifth-largest drug after Enbrel from Amgen, Takeda and Wyeth with sales swelling to $6 billion up from the present...

...into atrial fibrillation. Multaq, or dronedarone, will be sold in 400-milligram tablets intended to be taken twice per day. Sanofi-Aventis plans to launch the drug this summer. The company estimates there are 2.5 million atrial fibrillation patients in the...

...-- ARKRAY, Inc. -- Becton, Dickinson and Company -- Eli Lilly and Company -- Terumo Corporation -- Animas Corporation -- Sanofi-Aventis -- Smiths Medical -- Apex Biotechnology Corp. -- Panasonic Corporation -- A. Menarini Diagnostics S.r.l. -- EKF-diagnostic...

...faced higher cancer risks. (SNY) had fallen hard amid concerns that patients and doctors worried about Lantus' safety. Sanofi-Aventis (SNY), the French drugmaker, announced a restructuring and plans to sell some labs in the U.S., U.K., Japan and Spain. It...

...from any cause by 24 percent, compared to an inactive placebo, the FDA said. The most common side effects were diarrhea, nausea, vomiting, fatigue and weakness. Multaq is produced by French drug maker Sanofi-Aventis. The FDA has more about this approval....

... Today Alex Shimmings Please Login to read the full article. Sanofi-Aventis's amiodarone follow-up Multaq (dronedarone) has finally received its first approval, in the US. Launch there is planned in the next few months. The drug, which...

...Company Overview 133 12.10.2 Value Chain Analysis 133 12.11 Animas Corporation 135 12.11.1 Company Overview 135 12.12 Sanofi-Aventis 135 12.12.1 Company Overview 135 12.13 Smiths Medical 136 12.13.1 Company Overview 136 12.13.2 Value Chain Analysis...

...US FDA is reviewing many sources of safety data for Sanofi-Aventis's long-acting (once-daily) insulin analogue Lantus (insulin glargine) to better understand the risk, if any, for cancer. It is discussing with Sanofi-Aventis as to whether any additional...